Real-world outcomes associated with vonoprazan-based <i>versus</i> proton pump inhibitor-based therapy for <i>Helicobacter pylori</i> infection in Japan.

"ES, EEC, and HG are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Phathom Pharmaceuticals, which funded the development and conduct of this study and manuscript. KY was an employee of Analysis Group, Inc. at the time of study conduct.: CP and RJ are employees of Phathom Pharmaceuticals.: CWH is a consultant for Phathom Pharmaceuticals, RedHill Biopharma, Allakos, Ironwood, Neurogastrx, ISOThrive, and EndoStim. He is a speaker for RedHill Biopharma, Phathom, and Alnylman. He owns stock in Antibe Therapeutics.: KS is a consultant for Fuji Film Inc., Biofermin Pharma, and Pathom Pharmaceuticals. He received lecture fees from Takeda Pharmaceutical, Mylan Inc., Japan, Zeria Pharmaceuticals, Biofermin Pharma, and Astra-Zeneca Japan."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Financial support for this research was provided by Phathom Pharmaceuticals."